This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Torrisi, R. Articles by Decensi, A. Search for Related Content PubMed PubMed Citation Articles by Torrisi, R. Articles by Decensi, A.

The Synthetic Retinoid Fenretinide Lowers Plasma Insulin-like Growth Factor I Levels in Breast Cancer Patients¹

Department of Medical Oncology II [R. T., F. P., E. C., F. B., A. D.] and Biostatistics [M. A. O.], National Institute for Cancer Reserch and the University Department of Endocrinology [P. P.], 16132, Genova, Italy and the National Tumor Institute [A. C.], 20133, Milano, Italy

We studied the effect of fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)], a synthetic analogue of retinoic acid, on plasma insulin-like growth factor I (IGF-I) levels in a consecutive cohort of stage I breast cancer patients belonging to a randomized phase III trial of breast cancer chemoprevention. Thirty-two women receiving 4-HPR 200 mg/daily and 28 untreated controls entered the study. IGF-I levels were determined, after acid-ethanol extraction, on plasma obtained at randomization and after a mean time of 10.8 ± 0.3 months.

At baseline, there was no difference in IGF-I levels between the two groups [152.9 ± 9.4 versus 159.2 ± 7.0 ng/ml in treated and control group (P = 0.59), respectively]. After follow-up time, while plasma IGF-I levels were unchanged in control patients (163.3 ± 7.4 ng/ml; P = 0.5), they were significantly reduced to 134.6 ± 8.1 ng/ml in the patients treated with 4-HPR (P = 0.003 and P = 0.011 versus baseline and control values, respectively). Multiple regression analysis showed that treatment was the only determinant of IGF-I decline. Moreover, the interaction between treatment and age was significant, in that the decrease of IGF-I levels induced by 4-HPR administration was much more pronounced in younger patients, while an age-related decline was observed in controls.

We conclude that the synthetic retinoid 4-HPR lowers circulating IGF-I levels in early breast cancer patients. Although the importance of this observation for the clinical prevention of breast cancer remains to be established, it further substantiates the rationale of the combination of 4-HPR with tamoxifen, which is known to decrease IGF-I as well and to act synergistically with the retinoid in preclinical models.

¹ This work was partially supported by National Cancer Institute/NIH Grants CA56457 and CA38567 and by a grant from the Associazione Italiana per la Ricerca sul Cancro (A. I. R. C.).

² To whom requests for reprints should be addressed, at Servizio di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, viale Benedetto XV, No. 10, 16132, Genoa, Italy.

Received 8/ 2/93. Accepted 9/ 2/93.

This article has been cited by other articles:

				A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, et al. Randomized Double-Blind 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women J. Clin. Oncol., August 10, 2009; 27(23): 3749 - 3756. [Abstract] [Full Text] [PDF]

				L. Baglietto, D. R. English, J. L. Hopper, H. A. Morris, W. D. Tilley, and G. G. Giles Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 763 - 768. [Abstract] [Full Text] [PDF]

				U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Ann. Onc., July 1, 2006; 17(7): 1065 - 1071. [Abstract] [Full Text] [PDF]

				S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68. [Abstract] [Full Text] [PDF]

				A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, et al. Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women J. Clin. Oncol., January 1, 2006; 24(1): 129 - 135. [Abstract] [Full Text] [PDF]

				D. Serrano, L. Baglietto, H. Johansson, F. Mariette, R. Torrisi, M. Onetto, M. Paganuzzi, and A. Decensi Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer Clin. Cancer Res., March 1, 2005; 11(5): 2083 - 2088. [Abstract] [Full Text] [PDF]

				V. K. Puduvalli, J. T. Li, L. Chen, and I. E. McCutcheon Induction of Apoptosis in Primary Meningioma Cultures by Fenretinide Cancer Res., February 15, 2005; 65(4): 1547 - 1553. [Abstract] [Full Text] [PDF]

				A. Decensi, B. Bonanni, L. Baglietto, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, C. Robertson, I. Marinucci, F. Mariette, M. T. Sandri, et al. A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers Clin. Cancer Res., July 1, 2004; 10(13): 4389 - 4397. [Abstract] [Full Text] [PDF]

				A. Decensi, U. Veronesi, R. Miceli, H. Johansson, L. Mariani, T. Camerini, M. G. Di Mauro, E. Cavadini, G. De Palo, A. Costa, et al. Relationships between Plasma Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 and Second Breast Cancer Risk in a Prevention Trial of Fenretinide Clin. Cancer Res., October 15, 2003; 9(13): 4722 - 4729. [Abstract] [Full Text] [PDF]

				A. L. Sabichi, M. R. Modiano, J. J. Lee, Y.-M. Peng, M.-J. Xu, H. Villar, W. S. Dalton, and S. M. Lippman Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide Clin. Cancer Res., July 1, 2003; 9(7): 2400 - 2405. [Abstract] [Full Text] [PDF]

				F. Formelli, T. Camerini, E. Cavadini, V. Appierto, M. G. Villani, A. Costa, G. De Palo, M. G. Di Mauro, and U. Veronesi Fenretinide Breast Cancer Prevention Trial: Drug and Retinol Plasma Levels in Relation to Age and Disease Outcome Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 34 - 41. [Abstract] [Full Text] [PDF]

				A. Decensi, U. Omodei, C. Robertson, B. Bonanni, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, S. Mora, M. T. Sandri, M. Cazzaniga, et al. Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women Circulation, September 3, 2002; 106(10): 1224 - 1228. [Abstract] [Full Text] [PDF]

				C. S. Carter, M. M. Ramsey, R. L. Ingram, A. B. Cashion, W. T. Cefalu, Z.Q. Wang, and W. E. Sonntag Models of Growth Hormone and IGF-1 Deficiency: Applications to Studies of Aging Processes and Life-Span Determination J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2002; 57(5): B177 - 188. [Abstract] [Full Text]

				A. Decensi, H. Johansson, R. Miceli, L. Mariani, T. Camerini, E. Cavadini, M. G. Di Mauro, A. Barreca, A. G. Gonzaga, S. Diani, et al. Long-Term Effects of Fenretinide, a Retinoic Acid Derivative, on the Insulin-like Growth Factor System in Women with Early Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1047 - 1053. [Abstract] [Full Text] [PDF]

				S. Menard, T. Camerini, L. Mariani, G. Tomasic, S. Pilotti, A. Costa, G. De Palo, and U. Veronesi Re: Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer J Natl Cancer Inst, February 7, 2001; 93(3): 240 - 241. [Full Text] [PDF]

				G. J. Kelloff, C. C. Sigman, K. M. Johnson, C. W. Boone, P. Greenwald, J. A. Crowell, E. T. Hawk, and L. A. Doody Perspectives on Surrogate End Points in the Development of Drugs that Reduce the Risk of Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 127 - 137. [Abstract] [Full Text]

				U. Veronesi, G. De Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. R. Del Turco, M. G. Di Mauro, et al. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1847 - 1856. [Abstract] [Full Text] [PDF]

				H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide Carcinogenesis, February 1, 1999; 20(2): 229 - 236. [Abstract] [Full Text] [PDF]

				R. Lieberman, J. A. Crowell, E. T. Hawk, C. W. Boone, C. C. Sigman, and G. J. Kelloff Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring Clin. Chem., February 1, 1998; 44(2): 420 - 427. [Abstract] [Full Text] [PDF]

				J. A. O'Shaughnessy Chemoprevention of Breast Cancer JAMA, May 1, 1996; 275(17): 1349 - 1353. [Abstract] [PDF]